Abstract

The present invention addresses the problem of providing a medical tape suitable for being affixed on a wound to promote wound healing of the skin or on a scar to suppress and prevent thickening, expansion, and extension of a scar after a wound has healed. According to the present invention, provided is a medical tape comprising: a stretchable and flexible base material made of rubber; an adhesive layer; and a release paper laminated in this order, the medical tape having a portion that has a restoring force and does not adhere, and a portion that adheres without having a restoring force.

IPC Classes  ?

• A61F 13/0246 - Adhesive bandages or dressings characterised by the skin-adhering layer
• A61F 13/00 - Bandages or dressingsAbsorbent pads

Abstract

Provided are a phthalocyanine dye represented by formula (1) and a method for producing the same. (In the formula, M, L, Q, R2, R3, R7, R8, R4, R5, R6, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, X2, and X3 are as defined in the claims.)

IPC Classes  ?

• C09B 47/04 - Phthalocyanines
• A61K 31/409 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
• A61K 31/695 - Silicon compounds
• A61K 47/56 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Provided is an antibacterial capsid capable of efficiently killing parasitic bacteria in cells.　The antibacterial capsid is: a phage preparation for intracellular parasitic bacteria; or the like. The antibacterial capsid includes a capsid protein such as a phage that presents an intracellular localization signal on a surface. The intracellular localization signal may be a peptide that binds to a receptor for a nutrient necessary for an intracellular parasitic bacterium. The receptor may be a transferrin receptor or an oxLDL receptor. The intracellular parasitic bacterium may be an acid-fast bacterium that survives within the phagosome of a cell. The acid-fast bacterium includes any one of a bacterium belonging to the genus Mycobacterium, a bacterium belonging to the genus Mycolicibacillus, a bacterium belonging to the genus Mycolicibacter, a bacterium belonging to the genus Mycolicibacterium, and a bacterium belonging to the genus Mycobacteroides.

IPC Classes  ?

• C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 31/04 - Antibacterial agents
• C12N 15/33 - Genes encoding viral proteins
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

The present invention provides a vascular smooth muscle cell-tropic capsid which has an enhanced rate of infection to a vascular smooth muscle.　The present invention provides a capsid of an adeno-associated virus, the capsid being characterized in that a factor of tropism for vascular smooth muscle cells is added thereto. The factor of tropism is a peptide that is presented on the surface of a virus particle.　The peptide includes any one of "RENKLGE", "KDTVPRE", "TETGKTA", "STPAAKE", "RNREPTE", "ARNGTTE", "KDTAERQ", "NRGGNQD", "NRPDTNS", and "TRATSQE" in cases where vascular smooth muscle cells of a mouse (Mus musculus) are to be infected. The peptide includes any one of "NRPETNP", "SHDPSKE", "SEIRRDQ", "NRNKHEE", "RQDNKME", "THPPAPQ", "TRGGGSE", "TEKQTNS", "RVTMGSE", and "ATKNQNE" in cases where vascular smooth muscle cells of human (Homo sapiens) are to be infected.

IPC Classes  ?

• C07K 14/015 - Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/34 - Proteins from DNA viruses
• C12N 15/864 - Parvoviral vectors
• C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Abstract

The purpose of the present invention is to adjust the concentration of an in-vivo substance or a drug in an in-vivo semi-closed system, for example, to improve or suppress the intraocular concentration of an intravitreal formulation, for example, a vitreous body injection formulation such as an anti-VEGF drug. The present invention provides a concentration regulator for an in-vivo substance or a drug in an in-vivo semi-closed system, the concentration regulator containing, as an active ingredient, a drug that promotes or suppresses the production or discharge of a body fluid in the in-vivo semi-closed system.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61P 27/02 - Ophthalmic agents
• A61P 27/06 - Antiglaucoma agents or miotics
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

This blood inspection method comprises a preparation step for preparing whole blood collected from a subject, a pretreatment step for pretreating the whole blood to prepare an analysis sample, a separation step for separating the analysis sample into individual components by liquid chromatography, and an analysis step for analyzing each of the separated components with a mass spectrometry device. The subject has undergone the administration of a first immunosuppressive agent and a second immunosuppressive agent, the first immunosuppressive agent comprising at least one component selected from the group consisting of tacrolimus, ciclosporin A, everolimus and sirolimus, and the second immunosuppressive agent comprising at least one component selected from the group consisting of mycophenolic acid and metabolites thereof. The separated components include the first immunosuppressive agent and the second immunosuppressive agent. With respect to the method, in the analysis of the components with the mass spectrometry device, the analysis is performed in a positive mode when the first immunosuppressive agent is analyzed as a target component, and the analysis is performed in a negative mode when the second immunosuppressive agent is analyzed as a target component.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 27/62 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosolsInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electric discharges, e.g. emission of cathode

Abstract

A method for preparing a sample from a specimen includes treating a biopsy tissue taken from a lung cancer patient with negative pressure in an isotonic solution to release a cell from the biopsy tissue, collecting the isotonic solution containing the released cell, and mixing the collected isotonic solution and a cytologic specimen collected from the lung cancer patient together to obtain a cell suspension, wherein the cytologic specimen is one or more selected from the group consisting of a bronchial lavage fluid, a bronchoalveolar lavage fluid, a bronchial scraping lavage fluid and a puncture needle lavage fluid, and wherein the biopsy tissue and the cytologic specimen contain a tumor cell.

IPC Classes  ?

• G01N 1/30 - StainingImpregnating
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The present invention provides a means whereby it is possible to clarify the mechanism of manifestation of symptoms, an illness, or dysfunction caused by mitochondrial dysfunction and prevent or treat symptoms, an illness, or dysfunction relating to the same mechanism of manifestation. One embodiment of the present invention relates to a ferroptosis inhibitor containing a compound represented by formula (I), a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof as an active ingredient. Another embodiment of the present invention relates to a medicine that contains the ferroptosis inhibitor as an active ingredient and is for use in the prevention or treatment of symptoms, an illness, or dysfunction relating to ferroptosis. Yet another embodiment of the present invention relates to a compound represented by formula (I-1), a salt thereof, or a solvate thereof. The present invention provides a means whereby it is possible to clarify the mechanism of manifestation of symptoms, an illness, or dysfunction caused by mitochondrial dysfunction and prevent or treat symptoms, an illness, or dysfunction relating to the same mechanism of manifestation. One embodiment of the present invention relates to a ferroptosis inhibitor containing a compound represented by formula (I), a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof as an active ingredient. Another embodiment of the present invention relates to a medicine that contains the ferroptosis inhibitor as an active ingredient and is for use in the prevention or treatment of symptoms, an illness, or dysfunction relating to ferroptosis. Yet another embodiment of the present invention relates to a compound represented by formula (I-1), a salt thereof, or a solvate thereof.

IPC Classes  ?

• C07D 491/06 - Peri-condensed systems
• A61K 31/473 - QuinolinesIsoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
• A61K 31/4741 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
• C07D 221/18 - Ring systems of four or more rings

Abstract

The present invention provides: a B-cell maturation antigen (BCMA) antibody containing light-chain variable (VL) regions and heavy-chain variable (VH) regions or an antigen-binding fragment of the antibody, wherein the amino acid sequences for complementarity determining region (CDR)1, CDR2 and CDR3 in each of the VL regions and CDR1, CDR2 and CDR3 in each of the VH regions are specified; and a chimeric antigen receptor containing the fragment.

IPC Classes  ?

• C12N 15/13 - Immunoglobulins
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/02 - Antineoplastic agents specific for leukemia
• A61P 37/04 - Immunostimulants
• C07K 14/725 - T-cell receptors
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 19/00 - Hybrid peptides
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/12 - Genes encoding animal proteins
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Abstract

The problem addressed by the present invention is to provide a testing method that makes it possible to predict a prognosis for metastatic hormone-sensitive prostate cancer, which has a high possibility of a bad prognosis, via a means capable of being applied in a clinical setting.　The present invention relates to a testing method for prognosis prediction for metastatic hormone-sensitive prostate cancer, including a step for measuring the expression level of one or two genes selected from among an androgen receptor gene and an osteoglycin gene, or the expression level of a transcription product thereof, in prostate tissue collected from a metastatic hormone-sensitive prostate cancer patient.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12N 15/12 - Genes encoding animal proteins
• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12Q 1/6813 - Hybridisation assays

Abstract

The present invention includes a method for examining the progression of chronic kidney disease in a subject. The method includes measuring the creatinine concentration in the blood and urine of the subject and the phosphorus concentration in the urine. Next, an estimate for the phosphorous concentration in the primary urine on the basis of Formula (II): The present invention includes a method for examining the progression of chronic kidney disease in a subject. The method includes measuring the creatinine concentration in the blood and urine of the subject and the phosphorus concentration in the urine. Next, an estimate for the phosphorous concentration in the primary urine on the basis of Formula (II): ePTFp = Up Ucr × Scr × 3.33 ( II ) The present invention includes a method for examining the progression of chronic kidney disease in a subject. The method includes measuring the creatinine concentration in the blood and urine of the subject and the phosphorus concentration in the urine. Next, an estimate for the phosphorous concentration in the primary urine on the basis of Formula (II): ePTFp = Up Ucr × Scr × 3.33 ( II ) is calculated, followed by comparing the estimate for the phosphorus concentration in the primary urine with the phosphorus concentration in the primary urine of a normal subject. Another aspect of the invention relates to a method for suppressing the progression of chronic kidney disease in a non-human mammal subject.

IPC Classes  ?

• G01N 33/70 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving creatine or creatinine
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Provided is a peritoneal seeding inhibitor that efficiently inhibits peritoneal seeding. The peritoneal seeding inhibitor comprises an adeno-associated virus vector loaded with miR-29b. The serotype of this adeno-associated virus vector includes at least one type selected from AAV1, AAV2, AAV4, and AAV-DJ. More specifically, the serotype of the adeno-associated virus vector is AAV1, AAV2, AAV5, or AAV-DJ in humans (Homo sapiens), and is AAV1, AAV2, AAV5, AAV9, or AAV-DJ in mice (Mus musculus). Through this peritoneal seeding inhibitor, miR-29b is expressed in cells constituting the peritoneal cavity, and peritoneal seeding is treated or prevented.

IPC Classes  ?

• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 35/04 - Antineoplastic agents specific for metastasis
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 15/864 - Parvoviral vectors

Abstract

The present invention provides a means for quantifying and analyzing an analyte containing a mycophenolic acid and one or more other immunosuppressants by using the whole blood fraction without separating a blood sample. One aspect of the present invention pertains to a method for quantifying an analyte containing a mycophenolic acid and one or more other immunosuppressants in a target blood sample, the method comprising: an analyte concentration measurement step for measuring the concentration of an analyte containing a mycophenolic acid and one or more other immunosuppressants in the whole blood fraction of the blood sample; a hematocrit value acquisition step for acquiring a hematocrit value of the target blood sample; and a mycophenolic acid concentration conversion step for converting the concentration of the mycophenolic acid in the whole blood fraction of the blood sample to the concentration of the mycophenolic acid in a plasma fraction of the blood sample on the basis of the hematocrit value.

IPC Classes  ?

• G01N 33/49 - Physical analysis of biological material of liquid biological material blood
• A61K 31/365 - Lactones
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

Abstract

For example, therapeutic methods and the like for novel IL-8-related diseases using an IL-8 signal inhibitor are provided. Alternatively, for example, therapeutic methods and the like for known or novel IL-8-related diseases using a novel anti-IL-8 antibody are provided.

IPC Classes  ?

• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 15/00 - Drugs for genital or sexual disordersContraceptives
• A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• A61P 17/06 - Antipsoriatics
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The present invention addresses the problem of providing a novel radiation damage protection agent. The present invention provides a radiation damage protection agent that contains an adipose tissue or an adipose tissue-derived product [for example, a stromal vascular fraction (SVF)], a micronized cellular adipose matrix (MCAM) or an adipose-derived stem/stromal cell (ASC).

IPC Classes  ?

• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61K 35/35 - Fat tissueAdipocytesStromal cellsConnective tissues
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• A61P 39/00 - General protective or antinoxious agents

Abstract

The present invention provides a bacteria-targeting capsid particle that is non-proliferating and that has a high bactericidal effect.　A capsid protein of a phage is prepared with a capsid nucleic acid element that is separated from a phage genome, that does not include a packaging region, that mainly includes a virion region, and that synthesizes a capsid. An element for a bacteria-targeting capsid particle (B-CAP) includes a nucleic acid injection region, a replication region necessary for nucleic acid replication, and a packaging region which are separated from a portion of a phage genome other than a capsid nucleic acid element. A bacteria-targeting capsid particle (B-CAP) in which these are assembled is non-proliferating and enables inclusion of long-chain DNA which gives a new biological function including a bactericidal effect.

IPC Classes  ?

• C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 31/04 - Antibacterial agents
• C12N 15/31 - Genes encoding microbial proteins, e.g. enterotoxins
• C12N 15/70 - Vectors or expression systems specially adapted for E. coli
• C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora

Abstract

It is an object of the present invention to provide a detoxified secretome extract of a culture supernatant having high efficacy and high safety, and a method for producing the same. According to the present invention, provided is a detoxified secretome extract of a culture supernatant of mesenchymal stem cells or progenitor cells derived from the mesenchymal stem cells, wherein the detoxified secretome extract comprises at least one of IGFBP, HGF, VEGF, PDGF, EGF, KGF (FGF-7), PDGFR, TGFα, and TGFβ secreted by the mesenchymal stem cells or the progenitor cells derived from the mesenchymal stem cells, and wherein lactic acid and ammonia that are metabolic waste products caused by the mesenchymal stem cells or the progenitor cells derived from the mesenchymal stem cells are removed from the detoxified secretome extract.

IPC Classes  ?

• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• C07K 14/475 - Growth factorsGrowth regulators

Abstract

The present invention provides a chimeric receptor comprising: a first polypeptide which has (i) a first extracellular region binding to a ligand, (ii) a first transmembrane region, and (iii) a first intracellular region derived from an IL-2 receptor β chain, and in which a mutation is introduced to a tyrosine residue in the first intracellular region; and a second polypeptide which has (iv) a second extracellular region binding to a ligand, (v) a second transmembrane region, and (vi) a second intracellular region derived from an IL-2 receptor γ chain.

IPC Classes  ?

• C12N 15/62 - DNA sequences coding for fusion proteins
• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• A61P 35/00 - Antineoplastic agents
• C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
• C07K 19/00 - Hybrid peptides
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/12 - Genes encoding animal proteins
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

The present invention provides a nucleic acid construct or the like containing an inducible promoter and a sequence for encoding an adeno-associated virus (AAV) Cap protein that is operably linked to the promoter.

IPC Classes  ?

• C12N 15/864 - Parvoviral vectors
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
• C12N 15/35 - Parvoviridae, e.g. feline panleukopenia virus, human parvovirus

Abstract

12312322 or a partial protein thereof has protein C activity. This polypeptide or a partial polypeptide thereof enables: 1) the production of the activated protein C in the form of a recombinant preparation; and 2) the use thereof in effective gene therapy for protein C deficiency.

IPC Classes  ?

• C12N 15/57 - Hydrolases (3) acting on peptide bonds (3.4)
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61K 38/36 - Blood coagulation or fibrinolysis factors
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 7/02 - Antithrombotic agentsAnticoagulantsPlatelet aggregation inhibitors
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin
• C12N 15/864 - Parvoviral vectors

Abstract

[Problem] To provide a malaria vaccine which has an excellent preventative effect against infection and excellent effect of inhibiting malaria transmission, as compared to conventional malaria vaccines. [Solution] It was found that using, as a prime, a recombinant vaccinia virus which includes a gene that codes a CSP amino acid sequence and a gene that codes an s25 amino acid sequence, and using, as a boost, a recombinant adeno-associated virus which includes a gene that codes a CSP amino acid sequence and a gene that codes an s25 amino acid sequence results in a malaria vaccine which has an excellent preventative effect against infection and excellent effect of inhibiting malaria transmission.

IPC Classes  ?

• A61K 39/015 - Hemosporidia antigens, e.g. Plasmodium antigens
• A61K 39/23 - Parvoviridae, e.g. feline panleukopenia virus
• A61K 39/285 - Vaccinia virus or variola virus
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 33/06 - Antimalarials
• A61P 37/04 - Immunostimulants
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
• C12N 15/30 - Genes encoding protozoal proteins, e.g. from Plasmodium, Trypanosoma, Eimeria
• C12N 15/863 - Poxviral vectors, e.g. vaccinia virus
• C12N 15/864 - Parvoviral vectors
• A61K 35/76 - VirusesSubviral particlesBacteriophages

Abstract

Provided is a temporary treatment medium for inhibiting embryo developmental arrest due to manipulation of an embryo or the like. A temporary treatment medium according to the present invention reduces damage to an in-vitro culture due to manipulation thereof, said in-vitro culture containing one of pluripotent stem cells, reproductive cells, a fertilized egg, and an embryo or any combination thereof. For this purpose, the temporary treatment medium contains a cytoskeleton regulator and/or an apoptosis inhibitor. The cytoskeleton regulator and/or the apoptosis inhibitor is preferably an Rho kinase inhibitor. Specifically, a Rock inhibitor can be used as the Rho kinase inhibitor. The Rock inhibitor is, for example, Y-27632. The temporary treatment medium is used for treating an in-vitro culture for a specific period before and/or after manipulation involving damage thereto.

IPC Classes  ?

• C12N 5/073 - Embryonic cells or tissuesFoetal cells or tissues
• C12N 15/877 - Techniques for producing new mammalian cloned embryos

Abstract

The present invention provides a novel means of gene therapy for neurodegenerative diseases caused by an iron metabolic disorder. Specifically, the present invention provides a recombinant adeno-associated virus (rAAV) vector which contains a polynucleotide encoding WDR45 and improves the intracellular expression level of NCOA4. The rAAV vector according to the present invention is useful for the treatment of iron-accumulating neurodegenerative diseases such as SENDA. Also, the present invention provides a method for identifying cells originating in a patient suffering from a neurodegenerative disease, and a method for screening a substance which improves the intracellular expression level of NCOA4 for the treatment of a neurodegenerative disease.

IPC Classes  ?

• C12N 15/864 - Parvoviral vectors
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C12Q 1/6874 - Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation [SBH]
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

Provided is an asymmetric cell division inhibitor with which infertility due to aging or the like can be ameliorated.　The asymmetric cell division inhibitor includes a spontaneous activation inhibitor that inhibits asymmetric cell division caused by the spontaneous activation of cells having pluripotency. When the cells are reproductive cells or ova, spontaneous activation occurs due to aging or exposure to carbon dioxide before fertilization. The spontaneous activation is accompanied by the dispersion of chromosomes. Therefore, the asymmetric cell division inhibitor inhibits asymmetric cell division by inducing the inhibition of spontaneous activation and/or the reaggregation of dispersed chromosomes. Specifically, the spontaneous activation inhibitor may be a proteasome inhibitor, and includes MG132 or ALLN. The treatment in an in vitro fertilization medium containing the collected asymmetric cell division inhibitor can inhibit the asymmetric cell division of reproductive cells or fertilized ova.

IPC Classes  ?

• C12N 5/073 - Embryonic cells or tissuesFoetal cells or tissues
• A01K 67/02 - Breeding vertebrates
• A61K 38/06 - Tripeptides
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 15/00 - Drugs for genital or sexual disordersContraceptives
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07K 5/08 - Tripeptides
• C12N 5/074 - Adult stem cells

Abstract

The present invention addresses the problem of providing an anticancer agent and/or a cardiac-function-improving agent having a novel action mechanism. A pharmaceutical composition containing, as an active ingredient, a substance that inhibits binding between a Kruppel-like factor 5 (KLF5) and a ubiquitin-specific peptidase 3 (USP3), in particular, any one of the compounds represented by formulas (I)-(III) or a pharmaceutically acceptable salt thereof, is useful as an anticancer agent and/or a cardiac-function-improving agent.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 31/5395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07D 498/04 - Ortho-condensed systems
• G01N 33/15 - Medicinal preparations
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention provides a means whereby it is possible to clarify the mechanism of manifestation of symptoms, an illness, or dysfunction caused by mitochondrial dysfunction and prevent or treat symptoms, an illness, or dysfunction relating to the same mechanism of manifestation. One embodiment of the present invention relates to a ferroptosis inhibitor containing a compound represented by formula (I), a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof as an active ingredient. Another embodiment of the present invention relates to a medicine that contains the ferroptosis inhibitor as an active ingredient and is for use in the prevention or treatment of symptoms, an illness, or dysfunction relating to ferroptosis. Yet another embodiment of the present invention relates to a compound represented by formula (I-1), a salt thereof, or a solvate thereof.

IPC Classes  ?

• C07D 221/18 - Ring systems of four or more rings
• A61K 31/473 - QuinolinesIsoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
• A61K 31/4741 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 5/00 - Drugs for disorders of the endocrine system
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 13/02 - Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 27/02 - Ophthalmic agents
• A61P 31/04 - Antibacterial agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07D 491/06 - Peri-condensed systems

Abstract

A medical instrument, comprising a flexible strap portion having a proximal end and a distal end; a head portion distally extending from and connected to the distal end of the strap portion; and a tail portion proximally extending from and connected to the proximal end of the strap portion; wherein the head portion and the strap portion have a locking feature that allows the strap portion to be tightened to the head portion at a desired position, a loop having a desired size composed of a distal end side part of the strap portion and the head portion can be formed when tightened by the locking feature, and a plurality of features for keeping connected to thread are along the longitudinal direction on at least the distal end side part of the strap portion that forms the loop.

IPC Classes  ?

• A61B 17/12 - Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
• A61B 17/04 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for suturing woundsHolders or packages for needles or suture materials

Abstract

A medical instrument, comprising a flexible band body having a distal end and a proximal end; a flexible first rod-shaped body having a distal end and a proximal end; and a flexible second rod-shaped body having a distal end and a proximal end, wherein the distal end of the band body and the proximal end of the first rod-shaped body are connected, the distal end of the first rod-shaped body and the proximal end of the second rod-shaped body are connected via a connecting portion, the band body is more flexible than the first rod-shaped body and the second rod-shaped body, the second rod-shaped body has a locking part, the band body has a locking corresponding part, when tightened the locking part and the locking corresponding part, the proximal end of the first rod-shaped body and the distal end of the second rod-shaped body are connected via a part of the band body, the connecting portion is inflected, and a loop having a desired size can be formed by the first rod-shaped body, the second rod-shaped body and the part of the band body, and the second rod-shaped body further has a feature for placing the rest of the band body along an outer surface of the second rod-shaped body in the direction from the distal end to the proximal end of the second rod-shaped body when had been tightened the locking part and the locking corresponding part.

IPC Classes  ?

• A61B 17/122 - Clamps or clips, e.g. for the umbilical cord

Abstract

The present invention provides a ligating device having a first jaw part that has a distal end and a proximal end, a second jaw part that has a distal end and a proximal end, and a lock mechanism, the first jaw part and the second jaw part being linked so as to be capable of rotating about the respective proximal-end sides. The lock mechanism comprises a combination of a portion installed on the distal-end side of the first jaw part and a portion installed on the distal-end side of the second jaw part, and is configured so as to be: capable of linking the distal-end side of the first jaw part and the distal-end side of the second jaw part in a a manner enabling adjustment of the distance over which the inner surface of the first jaw part and the inner surface of the second jaw part hold a target organ therebetween; and capable, through the adjustment of said holding distance, of changing the force by which the target organ is clamped.

IPC Classes  ?

• A61B 17/122 - Clamps or clips, e.g. for the umbilical cord
• A61B 17/128 - Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord for applying or removing clamps or clips

Abstract

A method for preparing a stromal vascular fraction from an adipose tissue, including a step of treating an adipose tissue with an enzyme solution containing a collagenase and a neutral protease, preferably an enzyme solution free of clostripain and thermolysin, and showing not less than 1 U neutral protease activity with respect to 10,000 U collagenase activity, and recovering cells is provided by the present invention.

IPC Classes  ?

• C12N 9/52 - Proteinases derived from bacteria
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells

Abstract

The present invention provides a simple examination means for promptly identifying the progression of chronic kidney disease. One aspect of the present invention relates to a method for examining the progression of chronic kidney disease in a subject, said method including the following steps: a measurement step for measuring the creatinine concentration in the blood and urine of the subject and the phosphorous concentration in the urine; a calculation step for calculating an estimate for the phosphorous concentration in the primary urine on the basis of formula (II); and a phosphorous concentration comparison step for comparing the estimate for the phosphorous concentration in the primary urine, as obtained in the calculation step, with the phosphorous concentration in the primary urine of a normal subject. Another aspect of the present invention relates to a method for suppressing the progression of chronic kidney disease in a non-human mammal subject.

IPC Classes  ?

• G01N 33/493 - Physical analysis of biological material of liquid biological material urine
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/70 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving creatine or creatinine

Abstract

The present application provides a novel means for treating ornithine transcarbamylase deficiency. More specifically, the present application provides a modified adeno-associated virus vector which expresses ornithine transcarbamylase so that an attack from a neutralizing antibody in blood is reduced and a gene is efficiently introduced into a liver of a living body (for example, human). The present application provides, for example, a modified adeno-associated virus vector which expresses ornithine transcarbamylase, which contains a modified VP1 protein that contains, for example, an amino acid sequence obtained by substituting at least one of the 472th amino acid, the 587th amino acid, and the 706th amino acid in the amino acid sequence of the VP1 protein with another amino acid, and which does not cross-react with a neutralizing antibody against AAV2.

IPC Classes  ?

• C12N 15/864 - Parvoviral vectors
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61K 38/45 - Transferases (2)
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

This tool is for treating an excised end of a body organ and is provided with: a long and thin, flexible first band section having a distal end and a proximal end that are made of a biodegradable-absorptive polymer; a long and thin, flexible second band section having a distal end and a proximal end that are made of a biodegradable-absorptive polymer; and a first locking section having a first ratchet claw made of a biodegradable-absorptive polymer, wherein the first locking section is formed at the distal end of the second band section, the distal end of the first band section and the proximal end of the second band section are joined together, at least one ratchet tooth that is capable of meshing with the first ratchet claw is formed on the external surface of the first band section, and the engagement of the ratchet tooth with the first ratchet claw forms a flattened ring which is used to bind a body organ so as to ligate a tube or cavity that opens at an excised end of the body organ.

IPC Classes  ?

• A61B 17/12 - Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord

Abstract

The present disclosure relates to estimating the likelihood that a subject will develop side effects such as uveitis after administration of brolucizumab. This method involves using the concentration of at least one protein and/or the proportion of Th2 cells among the CD4-positive lymphocytes in a body fluid such as anterior aqueous humor, serum, or blood that has been isolated from a subject before administration of brolucizumab as an indicator to estimate the likelihood that the subject will develop side effects after administration of brolucizumab.

IPC Classes  ?

• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Provided is a novel gene therapy means for neurological diseases including epilepsy. The present invention provides: a recombinant adeno-associated virus vector for use in the treatment of neurological diseases including epilepsy, which comprises a polynucleotide encoding a protein capable of improving the excitation-inhibiting function of an inhibitory synapse in vivo, preferably neuroligin-2 protein; a pharmaceutical composition comprising said recombinant vector; and others. The present invention also provides a method for treating a disease such as epilepsy using the recombinant vector.

IPC Classes  ?

• C12N 15/864 - Parvoviral vectors
• A61P 25/08 - AntiepilepticsAnticonvulsants
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• A61K 35/761 - Adenovirus
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

Abstract

It has been discovered that plasma samples from endometriosis patients contain a number of markers whose abundance is different from those in healthy individuals. It has also been discovered that, by measuring the abundance of those markers, whether or not a subject is affected by endometriosis can be diagnosed, the extent of endometrial fibrosis or adhesion in a subject can be determined, pain of a patient affected or suspected of being affected by endometriosis can be predicted, and pathological conditions of the patient can be monitored.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

A blood pressure-related information display device, for visualizing and displaying information relating to blood pressure surges, is provided with: a blood pressure surge detection unit which, from time series data of blood pressure which changes linked to the subject's pulse, detects a blood pressure surge on the basis of a preset determination standard; a bodily state input unit which, together with the time series data of blood pressure, inputs bodily state information which indicates the bodily state of the subject; an extraction unit which extracts a feature value of the blood pressure surge; a statistical processing unit which performs statistical processing of the extracted feature value of the blood pressure surge; a calculation unit which calculates a feature value of the subject's bodily state; a display processing unit which performs processing for displaying, on a display screen, the correlation between the feature value of the blood pressure surge which was subjected to statistical processing, and the feature value of the bodily state.

IPC Classes  ?

• A61B 5/022 - Measuring pressure in heart or blood vessels by applying pressure to close blood vessels, e.g. against the skinOphthaldynamometers
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

The present invention addresses the problem of providing: a purified concentrate of a culture supernatant, which has high effectiveness and high safety; and a method for producing the purified concentrate. According to the present invention, a purified concentrate of a culture supernatant of a mesenchymal stem cell or a progenitor cell derived from the mesenchymal stem cell is provided, the purified concentrate containing at least one component selected from IGFBP, HGF, VEGF, PDGF, EGF, KGF(FGF-7)，PDGFR, TGFα and TGFβ secreted from a mesenchymal stem cell or a progenitor cell derived from the mesenchymal stem cell, and lactic acid and ammonia that are metabolic waste products produced by a mesenchymal stem cell or a progenitor cell derived from the mesenchymal stem cell are removed from the purified concentrate.

IPC Classes  ?

• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

According to the present invention, blood pressure surges are detected from time-series data on blood pressure of a subject that varies with pulsation based on predetermined determination criteria. For each blood pressure surge thus detected, an envelope connecting a plurality of pulse-corresponding peaks forming the blood pressure surge is acquired as an individual waveform. Statistical processing is performed on a plurality of individual waveforms to obtain a representative waveform and waveform variation among the blood pressure surges in the time-series data. On a display screen, a curve indicating the representative waveform is displayed with the curve superimposed on a region indicating the waveform variation among the blood pressure surges.

IPC Classes  ?

• A61B 5/021 - Measuring pressure in heart or blood vessels
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

According to the present invention, blood pressure surges is detected from time-series data on blood pressure of a subject that varies with pulsation based on predetermined determination criteria. A feature amount indicating a characteristic of each blood pressure surge thus detected is obtained. Statistical processing is performed on an occurrence number of the blood pressure surges thus detected and/or the feature amount to obtain a statistical amount for each of time slots. A required attention degree indicating a level of attention being required to the blood pressure surge is obtained for each of the time slots based on the statistical amount of the occurrence number of the blood pressure surges and/or the feature amount. The required attention degree thus obtained and/or the statistical amount are displayed side by side for each of the time slots on a display screen.

IPC Classes  ?

• A61B 5/021 - Measuring pressure in heart or blood vessels
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G06T 11/00 - 2D [Two Dimensional] image generation
• G06T 11/20 - Drawing from basic elements, e.g. lines or circles

Abstract

Provided is a biomarker capable of specifically diagnosing acute kidney injury. An acute kidney injury-specific biomarker is a miRNA that is primarily present in the blood. The miRNA is miRNA-5100. Furthermore, miRNA-5100 can be used as a method for diagnosing acute kidney injury. In this diagnosis, when the expression of miRNA-5100 is decreased in the blood, it is diagnosed as acute kidney injury. As an acute kidney injury test kit, it is also possible to include a reagent for measuring miRNA-5100.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links

Abstract

The purpose of the present invention is to provide a viscoelastic composition having excellent operability, which is suitable for use in securing the field of view of an endoscope when opaque dark-colored liquid accumulates inside a canal and obstructs the field of view of the endoscope, the viscoelastic composition securing the field of view by pushing the liquid aside, and to provide a method for securing the field of view of an endoscope using the viscoelastic composition. The viscoelastic composition for securing the field of view of an endoscope comprises a substance having viscoelastic properties and water, preferably has a hardness of 550 N/m2 or less, a viscosity (25° C.) of 200 to 2,000 mPa·s, and a loss tangent of 0.6 or less, and more preferably has an electrical conductivity of 250 μS/cm or less. The method for securing the field of view of an endoscope comprises feeding the viscoelastic composition from a proximal part of the endoscope, through a channel, into a distal part of the endoscope.

IPC Classes  ?

• A61L 31/04 - Macromolecular materials
• A61L 31/14 - Materials characterised by their function or physical properties
• A61B 1/015 - Control of fluid supply or evacuation
• A61L 31/02 - Inorganic materials

Abstract

In order to provide a composition for treating, ameliorating or preventing Crohn's disease or the like, a test method for this disease, etc., the present inventors successfully isolated a small intestinal bacterium, said bacterium inducing the proliferation or activation of Th1 cells and/or Th17 cells relating to Crohn's disease, from a bacterial flora in the small intestinal mucosa of a patient with this disease.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• C12N 15/31 - Genes encoding microbial proteins, e.g. enterotoxins

Abstract

For example, therapeutic methods and the like for novel IL-8-related diseases using an IL-8 signal inhibitor are provided. Alternatively, for example, therapeutic methods and the like for known or novel IL-8-related diseases using a novel anti-IL-8 antibody are provided.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• A61P 15/00 - Drugs for genital or sexual disordersContraceptives
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A61P 17/06 - Antipsoriatics
• A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

This medical instrument comprises: a flexible band body that has a distal end and a proximal end; a flexible first rod-shaped body that has a distal end and a proximal end; and a flexible second rod-shaped body that has a distal end and a proximal end. The distal end of the band body and the proximal end of the first rod-shaped body are connected. The distal end of the first rod-shaped body and the proximal end of the second rod-shaped body are connected via a connection portion. The band body is more flexible than the first rod-shaped body and the second rod-shaped body. The second rod-shaped body has a locking portion. The band body has a corresponding locking portion. Tightly fastening together the locking portion and the corresponding locking portion links the proximal end of the first rod-shaped body and the distal end of the second rod-shaped body via part of the band body, bends the connection portion, and allows the first rod-shaped body, the second rod-shaped body, and said part of the band body to form a ring of a prescribed size. The second rod-shaped body further includes a mechanism that causes the remaining part of the band body to conform to the outer surface of the second rod-shaped body from the distal end toward the proximal end of the second rod-shaped body when the locking portion and the corresponding locking portion are tightly fastened.

IPC Classes  ?

• A61B 17/122 - Clamps or clips, e.g. for the umbilical cord

Abstract

A medical instrument comprising: a flexible strap portion that has a proximal end and a distal end; a head portion that is linked to the distal end of the strap portion and extends in the distal direction; and a tail portion that is linked to the proximal end of the strap portion and extends in the proximal direction, wherein the head portion and the strap portion have a lock mechanism that can tightly fasten the strap portion to the head portion at a desired position, tight fastening by the lock mechanism enables the head portion and a distal-end section of the strap portion to form a ring of a desired size, and at least the distal-end section of the strap portion forming the ring has a plurality of mechanisms along the lengthwise direction thereof for securing a thread.

IPC Classes  ?

• A61B 17/11 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for performing anastomosisButtons for anastomosis

Abstract

Provided is a temporary treatment medium for inhibiting embryo developmental arrest due to manipulation of an embryo or the like. A temporary treatment medium according to the present invention reduces damage to an in-vitro culture due to manipulation thereof, said in-vitro culture containing one of pluripotent stem cells, reproductive cells, a fertilized egg, and an embryo or any combination thereof. For this purpose, the temporary treatment medium contains a cytoskeleton regulator and/or an apoptosis inhibitor. The cytoskeleton regulator and/or the apoptosis inhibitor is preferably an Rho kinase inhibitor. Specifically, a Rock inhibitor can be used as the Rho kinase inhibitor. The Rock inhibitor is, for example, Y-27632. The temporary treatment medium is used for treating an in-vitro culture for a specific period before and/or after manipulation involving damage thereto.

IPC Classes  ?

• C12N 5/073 - Embryonic cells or tissuesFoetal cells or tissues
• C12N 5/0735 - Embryonic stem cellsEmbryonic germ cells
• C12N 5/075 - OocytesOogonia
• C12N 5/076 - Sperm cellsSpermatogonia
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
• C12N 15/877 - Techniques for producing new mammalian cloned embryos
• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
• A61L 27/38 - Animal cells

Abstract

A viscoelastic composition for securing the field of view of an endoscope, the viscoelastic composition comprising a thickening substance and water and having a shear storage modulus G′ of 0.7 Pa or more, and a method for securing the field of view of an endoscope, the method comprising feeding the viscoelastic composition from a proximal part of the endoscope, through a channel, into a distal part of the endoscope.

IPC Classes  ?

• A61L 31/14 - Materials characterised by their function or physical properties
• A61L 31/04 - Macromolecular materials
• A61B 1/012 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor characterised by internal passages or accessories therefor

Abstract

A physiological information processing apparatus including: a processor; and a memory that stores a computer-readable command. When the computer-readable command is executed by the processor, the physiological information processing apparatus acquires physiological information data indicating physiological information of a subject, acquires a value of a parameter relevant to an autonomic nerve function of the subject in each of first time intervals based on the physiological information data, acquires an abnormality index value indicating an extent of abnormality in the autonomic nerve function of the subject based on the values of the parameter acquired in the first time intervals respectively, and displays information relevant to the abnormality index value.

IPC Classes  ?

• A61B 5/388 - Nerve conduction study, e.g. detecting action potential of peripheral nerves
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
• G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof

Abstract

Provided is a method for maturing a cardiomyocyte, whereby it becomes possible to obtain a maturated mature cardiomyocyte. One component selected from the group consisting of a specific nuclear receptor agonist, a maturation-promoting compound and a transcriptional factor capable of promoting the maturation of a cardiomyocyte or an arbitrary combination of these components is added to an immature cardiomyocyte. As a result, the immature cardiomyocyte can be matured to give a mature cardiomyocyte. Among the above-mentioned components, a nuclear receptor agonist is one component selected from the group consisting of a hormone, an RXR agonist, a PPAR agonist and an ROR agonist or an arbitrary combination of these components, and the maturation-promoting compound is an HIF1a inhibitor.

IPC Classes  ?

• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• A61K 35/34 - MusclesSmooth muscle cellsHeartCardiac stem cellsMyoblastsMyocytesCardiomyocytes
• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
• A61L 27/38 - Animal cells
• A61L 27/40 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12Q 1/24 - Methods of sampling, or inoculating or spreading a sampleMethods of physically isolating an intact microorganism
• C12Q 1/6897 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

The present invention provides a method for preparing a stromal vascular cell population from adipose tissue, comprising a step of treating adipose tissue with an enzyme solution followed by the recovery of cells. The enzyme solution contains collagenase and a neutral protease, wherein the neutral protease activity is at least 1 U per 10,000 U of collagenase activity. The enzyme solution preferably does not contain clostripain and does not contain thermolysin.

IPC Classes  ?

• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells

Abstract

This tool is for treating an excised end of a body organ and is provided with: a long and thin, flexible first band section having a distal end and a proximal end that are made of a biodegradable-absorptive polymer; a long and thin, flexible second band section having a distal end and a proximal end that are made of a biodegradable-absorptive polymer; and a first locking section having a first ratchet claw made of a biodegradable-absorptive polymer, wherein the first locking section is formed at the distal end of the second band section, the distal end of the first band section and the proximal end of the second band section are joined together, at least one ratchet tooth that is capable of meshing with the first ratchet claw is formed on the external surface of the first band section, and the engagement of the ratchet tooth with the first ratchet claw forms a flattened ring which is used to bind a body organ so as to ligate a tube or cavity that opens at an excised end of the body organ.

IPC Classes  ?

• A61B 17/12 - Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord

Abstract

A genome editing method for an isolated cell, the method comprising introducing foreign DNA into a targeted genome with homologous recombination of at least one of a 5′-end or a 3′-end of the foreign DNA, where the foreign DNA has homology arms, each with a length of less than 500 bp.

IPC Classes  ?

• C12N 15/90 - Stable introduction of foreign DNA into chromosome
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 5/0789 - Stem cellsMultipotent progenitor cells
• C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
• A61P 37/04 - Immunostimulants

Abstract

According to a conventional method for treatment of Sandhoff disease and Tay-Sachs disease comprising administering a modified β-subunit to a patient in the form of a protein, it is necessary that administration be performed frequently. This invention relates to a recombinant adeno-associated virus virion comprising: capsomere comprising a protein capable of forming a virus virion; and a polynucleotide packaged in the capsomere comprising a promoter sequence and nucleotide sequences operably linked to the promoter sequence encoding a first amino acid sequence derived from the amino acid sequence of the β-subunit of wild-type human β-hexosaminidase composed of amino acids 55 to 556 in the sequence as shown in SEQ ID NO: 28 by substitution of amino acids 312 to 318 with glycine, serine, glutamic acid, proline, serine, glycine, and threonine in that order and a second amino acid sequence, which is an amino acid sequence of a signal peptide linked to the N terminus of the first amino acid.

IPC Classes  ?

• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

The inventors of the present invention discovered that a plurality of markers in amounts differing from the amounts thereof in a normal subject are present in a blood plasma sample from an endometriosis patient. The inventors also discovered that by measuring the amounts of the markers present, it is possible to diagnose whether a subject is affected by endometriosis, the degree of fibrosis and adhesion of the endometrium in a subject can be determined, pain in a patient affected or suspected of being affected by endometriosis can be estimated, and the disease state of the patient can be monitored.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

A means for substantially improving mitochondrial dysfunction is provided. An aspect of the present invention relates to an agent for improving mitochondrial dysfunction, having a compound represented by the following formula, a stereoisomer or a salt thereof, or a solvate thereof, as an active ingredient. Another aspect of the present invention relates to a medicament or a pharmaceutical composition having the aforementioned compound, a stereoisomer or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, as an active ingredient, for use in preventing or treating a disease or symptom caused by mitochondrial dysfunction.

IPC Classes  ?

• A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
• A61K 31/473 - QuinolinesIsoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam

Abstract

The present invention provides a means for transferring a therapeutic gene of interest into a nervous system cell by a highly-efficient and simpler means. More specifically, the present invention provides a recombinant vector that uses an adeno-associated virus (AAV), a method for manufacturing the recombinant vector, and a method for using the recombinant vector. More specifically, recombinant adeno-associated virus virions, which are capable of passing through the brain-brain barrier, for transferring a therapeutic genes of interest into a nervous system cell in a highly-efficient manner, a drug composition containing the recombinant adeno-associated virus virions, a method for manufacturing the recombinant adeno-associated virus virions, and a kit or the like are provided.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• C12N 15/861 - Adenoviral vectors
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 38/18 - Growth factorsGrowth regulators
• A61K 38/44 - Oxidoreductases (1)
• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)

Abstract

According to the present invention, a blood pressure surge is detected from time-series data on a blood pressure that changes in association with the pulsation of a subject on the basis of a predetermined determination criterion. For each detected blood pressure surge, an envelope connecting a plurality of beat-correspondence peaks constituting the blood pressure surge is obtained as individual waveforms (C11, C12, C13, ...). The plurality of obtained individual waveforms (C11, C12, C13, ...) are statistically processed, so that a representative waveform and a waveform variation in the blood pressure surge in the time series data are obtained. A process is performed for displaying, on a display screen, a curved line (Cav) indicating the representative waveform while the curved line (Cav) is superimposed on an area (Sd) indicating the waveform variation in the blood pressure surge.

IPC Classes  ?

• A61B 5/022 - Measuring pressure in heart or blood vessels by applying pressure to close blood vessels, e.g. against the skinOphthaldynamometers

Abstract

In the present invention, blood pressure surges are detected on the basis of a predetermined determination criterion from time-series data of the blood pressure of a subject which varies with the pulsation (S2). Feature amounts indicating features of the detected blood pressure surges are calculated (S3). The frequency and/or feature amounts of the detected blood pressure surges are subjected to statistical processing for each time period to calculate statistical amounts (S4). The required attention level indicating the level of required attention to a blood pressure surge is determined for each time period on the basis of the statistical amounts of the frequency and/or feature amounts of the blood pressure surges (S5). A process of displaying the determined required attention levels and/or statistical amounts of the respective time periods side by side on a display screen is performed (S6).

IPC Classes  ?

• A61B 5/022 - Measuring pressure in heart or blood vessels by applying pressure to close blood vessels, e.g. against the skinOphthaldynamometers

Abstract

This device displays the correlation between a feature value of a blood pressure surge and a feature value of the bodily state when the blood pressure surge is detected. This blood pressure-related information display device, for visualizing and displaying information relating to blood pressure surges, is provided with: a blood pressure surge detection unit 310 which, from time series data of blood pressure which changes linked to the subject's pulse, detects a blood pressure surge on the basis of a preset determination standard; a bodily state input unit 310 which, together with the time series data of blood pressure, inputs bodily state information which indicates the bodily state of the subject; an extraction unit 310 which extracts a feature value of the blood pressure surge; a statistical processing unit 310 which performs statistical processing of the extracted feature value of the blood pressure surge; a calculation unit 310 which calculates a feature value of the subject's bodily state; and a display processing unit 310 which performs processing for displaying, on a display screen, the correlation between the feature value of the blood pressure surge which was subjected to statistical processing, and the feature value of the bodily state.

IPC Classes  ?

• A61B 5/022 - Measuring pressure in heart or blood vessels by applying pressure to close blood vessels, e.g. against the skinOphthaldynamometers

Abstract

The present invention relates to an endoscope visual field-securing viscoelastic composition containing a thickening substance and water, the composition having a shear storage elastic modulus G' of 0.7 Pa or higher, and to a method for securing the endoscope visual field, comprising sending the viscoelastic composition from the endoscope proximal part, through a channel, to the endoscope forward end portion. The viscoelastic composition or method according to the present invention can be used suitably, in particular, for securing the endoscope visual field, when an opaque, densely colored liquid or semi-solid has accumulated in the interior of a tube and blocked the endoscope visual field, by pushing aside the liquid or the semi-solid, or for securing the endoscope visual field when the endoscope visual field has been blocked by continuous bleeding in the interior of a tube.

IPC Classes  ?

• A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
• A61L 31/14 - Materials characterised by their function or physical properties

Abstract

The present invention relates to an endoscope visual field-securing viscoelastic composition containing a thickening substance and water, the composition having a shear storage elastic modulus G' of 0.7 Pa or higher, and to a method for securing the endoscope visual field, comprising sending the viscoelastic composition from the endoscope proximal part, through a channel, to the endoscope forward end portion. The viscoelastic composition or method according to the present invention can be used suitably, in particular, for securing the endoscope visual field, when an opaque, densely colored liquid or semi-solid has accumulated in the interior of a tube and blocked the endoscope visual field, by pushing aside the liquid or the semi-solid, or for securing the endoscope visual field when the endoscope visual field has been blocked by continuous bleeding in the interior of a tube.

IPC Classes  ?

• A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
• A61L 31/14 - Materials characterised by their function or physical properties

Abstract

Provided is a biomarker capable of specifically diagnosing diabetic nephropathy. The diabetic nephropathy-specific biomarker is miRNA which is primarily present in blood. The miRNA is miRNA-125b-5p and/or miRNA-181b-5p. Furthermore, it is possible to use this miRNA-125b-5p and/or miRNA-181b-5p as a method for diagnosing diabetic nephropathy. When making a diagnosis, diabetic nephropathy is diagnosed when miRNA-125b-5p expression in the blood increases and/or when miRNA-181b-5p expression in the blood decreases.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

Provided is a biomarker capable of specifically diagnosing acute renal failure. The acute renal failure-specific biomarker is miRNA which is primarily present in blood. The miRNA is miRNA-5100. Furthermore, it is possible to use this miRNA-5100 as a method for diagnosing acute renal failure. When making a diagnosis, acute renal failure is diagnosed when miRNA-5100 expression in the blood decreases. As a kit for testing for acute renal failure, it is possible to include a reagent which measures miRNA-5100.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

Provided is an antibacterial phage that selectively kills bacteria having a drug resistance gene or the like. The antibacterial phage contains CRISPR-Cas13a including a target sequence that recognizes a specific gene as a target. The target sequence is designed as a 14 to 28 bp crRNA spacer sequence. The specific gene is a drug resistance gene or a toxin. The drug resistance gene is included in the genome and/or plasmid of one or any combination of bacteria selected from the group consisting of methicillin-resistant Staphylococcus aureus, vancomycin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, penicillin-resistant Streptococcus pneumoniae, multi-drug resistant Pseudomonas aeruginosa, multiple drug resistant acinetobacter species, carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant Serratia marcescens, third-generation cephalosporin-resistant Streptococcus pneumoniae, third-generation cephalosporin-resistant Escherichia coli, and fluoroquinolone-resistant Escherichia coli.

IPC Classes  ?

• C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61P 31/04 - Antibacterial agents
• C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
• C12N 15/31 - Genes encoding microbial proteins, e.g. enterotoxins
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

A method for genome editing in an isolated cell, wherein the genome editing method is characterized in that foreign DNA having homology arms less than 500 bp in length is introduced into a target genome by homologous recombination of the 5' end and/or the 3' end of the foreign DNA.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61P 37/04 - Immunostimulants
• C12N 5/074 - Adult stem cells
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

Abstract

Provided are an epilepsy determination device, an epilepsy determination system, an epilepsy determination method and an epilepsy determination program, with which it is possible to determine an epileptic seizure with high accuracy. An epilepsy determination device (10) comprises: an acquisition unit (11) that acquires brainwave data of a subject; a generation unit (12) that extracts the brainwave data in prescribed time widths to generate a plurality of images representing brainwaves; and a determination unit (13) that inputs the plurality of images to a learned model (13a) to cause the determination to be made as to whether an epileptic seizure brainwave appears in any of the plurality of images.

IPC Classes  ?

• A61B 5/0476 - Electroencephalography
• A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements

Abstract

The present invention relates to a mitochondria-targeted lipid membrane structure encapsulating a nucleic acid represented by any of a) through d) below. a) RNA including, in this order, a first mitochondrial tRNA base sequence, a base sequence of mRNA encoding a target protein, and a second mitochondrial tRNA base sequence, the mRNA base sequence including one or more UGA as a tryptophan codon, b) DNA including a promoter base sequence and a base sequence complementary to the RNA of a), c) RNA including an mRNA base sequence encoding a target protein and a base sequence of a poly A chain present on the 3' end side thereof, the mRNA base sequence having one or more UGA as a tryptophan codon, AUG as a start codon, and UAA as a stop codon, d) DNA including a promoter base sequence and a base sequence complementary to the RNA of c).

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/12 - Genes encoding animal proteins
• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

In a conventional method for treating Sandhoff disease and Tay-Sachs disease by administering to a patient a modified β-subunit in the form of a protein, the administration needs to be performed at a high frequency. The present invention pertains to a recombinant adeno-associated virus virion comprising a capsomer which contains a protein capable of forming a virus virion and a polynucleotide which is packaged within the capsomer and comprises a promoter sequence and a base sequence operably linked to the promoter sequence, said base sequence encoding a first amino acid sequence, which is derived from the amino acid sequence of the 55th-556th amino acid sequence of the β-subunit of wild type human β-hexosaminidase (SEQ ID NO: 28) by substitution of the 312nd-318th amino acids into glycine, serine, glutamic acid, proline, serine, glycine and threonine in this order, and a second amino acid sequence which is the amino acid sequence of a signal peptide linked to the N-terminal side of the first amino acid sequence.

IPC Classes  ?

• C12N 15/35 - Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material

Abstract

For example, therapeutic methods and the like for novel IL-8-related diseases using an IL-8 signal inhibitor are provided. Alternatively, for example, therapeutic methods and the like for known or novel IL-8-related diseases using a novel anti-IL-8 antibody are provided.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• A61P 15/00 - Drugs for genital or sexual disordersContraceptives
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A61P 17/06 - Antipsoriatics
• A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention addresses the issue of providing a means for substantially improving mitochondrial dysfunction. One embodiment of this invention pertains to an agent for improving mitochondrial dysfunction, that includes, as an effective component thereof, a compound indicated by a formula, a stereoisomerism thereof, a salt of same, or a solvate of these. Another embodiment of this invention pertains to a pharmaceutical or a pharmaceutical composition for use in the prevention or treatment of diseases or symptoms caused by mitochondrial dysfunction, said pharmaceutical or a pharmaceutical composition including as an effective component thereof said compound, a stereoisomerism thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof.

IPC Classes  ?

• A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
• A61K 31/473 - QuinolinesIsoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
• A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 3/12 - Drugs for disorders of the metabolism for electrolyte homeostasis
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 27/02 - Ophthalmic agents
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Disclosed is a bioinformation measurement system that comprises: a first light-emitting part that applies light to a first region that is on a hand or a foot of a subject; a first light-receiving part that receives light that is reflected from or passes through the first region; a second light-emitting part that applies light to a second region that is on the head or the neck of the subject; a second light-receiving part that receives light that is reflected from or passes through the second region; a first measurement value generation part that, on the basis of changes in the amount of light received at the first light-receiving part, generates first measurement values that are associated with pulse wave and hemoglobin; and a second measurement value generation part that, on the basis of changes in the amount of light received at the second light-receiving part, generates second measurement values that are associated with pulse wave and hemoglobin.

IPC Classes  ?

• A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
• A61B 5/02 - Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
• A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters

Abstract

A bioinformation measurement device that comprises: a casing that is installed on a head surface of a living body; a light-emitting part that is provided to the casing and emits measurement light toward the skull of the living body; a light-receiving part that is provided to the casing, that receives light that is measurement light that has been emitted from the light-emitting part and reflected by the skull, and that outputs an electrical signal that corresponds to the amount of reflected light received; a bioinformation calculation part that, on the basis of the electrical signal outputted from the light-receiving part, calculates pulse wave information and hemoglobin information for the skull; and an inference part that, on the basis of the pulse wave information and the hemoglobin information calculated by the bioinformation calculation part, infers whether there is bleeding inside the skull.

IPC Classes  ?

• A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
• A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements

Abstract

This tool is for treating an excised end of a body organ and is provided with: a long and thin, flexible first band section having a distal end and a proximal end that are made of a biodegradable-absorptive polymer; a long and thin, flexible second band section having a distal end and a proximal end that are made of a biodegradable-absorptive polymer; and a first locking section having a first ratchet claw made of a biodegradable-absorptive polymer, wherein the first locking section is formed at the distal end of the second band section, the distal end of the first band section and the proximal end of the second band section are joined together, at least one ratchet tooth that is capable of meshing with the first ratchet claw is formed on the external surface of the first band section, and the engagement of the ratchet tooth with the first ratchet claw forms a flattened ring which is used to bind a body organ so as to ligate a tube or cavity that opens at an excised end of the body organ.

IPC Classes  ?

• A61B 17/12 - Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord

Abstract

The present invention addresses the problem of providing a novel compound having high LSD1 inhibitory activity, high selectivity for LSD1 inhibition, and/or having useful therapeutic effects for various diseases. One embodiment of the present invention relates to: a compound represented by formula (I) [in the formula, the meanings of L and A are as defined in the specification and claims], a stereoisomer thereof, a salt of the compound or the stereoisomer, or a solvate of the compound or the stereoisomer. Another embodiment of the present invention also relates to: a method for producing a compound represented by formula (I), a stereoisomer thereof or a salt of the compound or the stereoisomer, or a solvate of the compound or the stereoisomer; and an LSD1 inhibitor, a medicine and a pharmaceutical composition that contain said compound, the stereoisomer thereof, a salt of the compound or the stereoisomer, or a solvate of the compound or the stereoisomer as an effective component.

IPC Classes  ?

• C07C 217/74 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
• A61K 31/132 - Amines, e.g. amantadine having two or more amino groups, e.g. spermidine, putrescine
• A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
• A61K 31/4188 - 1,3-Diazoles condensed with heterocyclic ring systems, e.g. biotin, sorbinil
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/4995 - Pyrazines or piperazines forming part of bridged ring systems
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia
• C07C 213/08 - Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
• C07C 231/02 - Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
• C07C 237/04 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
• C07C 237/08 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
• C07C 237/10 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
• C07C 237/12 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
• C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
• C07D 207/14 - Nitrogen atoms not forming part of a nitro radical
• C07D 209/14 - Radicals substituted by nitrogen atoms, not forming part of a nitro radical
• C07D 209/54 - Spiro-condensed
• C07D 211/26 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
• C07D 211/56 - Nitrogen atoms
• C07D 211/58 - Nitrogen atoms attached in position 4
• C07D 211/62 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
• C07D 213/36 - Radicals substituted by singly-bound nitrogen atoms
• C07D 213/72 - Nitrogen atoms
• C07D 217/06 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ringAlkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
• C07D 221/20 - Spiro-condensed ring systems
• C07D 231/40 - Acylated on said nitrogen atom
• C07D 241/20 - Nitrogen atoms
• C07D 271/06 - 1,2,4-OxadiazolesHydrogenated 1,2,4-oxadiazoles
• C07D 295/185 - Radicals derived from carboxylic acids from aliphatic carboxylic acids
• C07D 295/192 - Radicals derived from carboxylic acids from aromatic carboxylic acids
• C07D 295/215 - Radicals derived from nitrogen analogues of carbonic acid
• C07D 305/08 - Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
• C07D 309/14 - Nitrogen atoms not forming part of a nitro radical
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 487/04 - Ortho-condensed systems
• C07D 487/08 - Bridged systems
• C07D 487/10 - Spiro-condensed systems
• C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Abstract

2 or less, a viscosity (25° C.) of 200 to 2,000 mPa·s, and a loss tangent of 0.6 or less, and more preferably has an electrical conductivity of 250 μS/cm or less. The method for securing the field of view of an endoscope comprises feeding the viscoelastic composition from a proximal part of the endoscope, through a channel, into a distal part of the endoscope.

IPC Classes  ?

• A61L 31/04 - Macromolecular materials
• A61L 31/14 - Materials characterised by their function or physical properties
• A61B 1/015 - Control of fluid supply or evacuation
• A61L 31/02 - Inorganic materials

Abstract

In order to provide a novel gene therapy means against hemophilia, the present invention provides a recombinant adeno-associated virus (rAAV) vector for treating disorders related to blood clotting. This virus vector includes a virus genome including: a liver-specific promoter sequence; and a polynucleotide sequence that codes for a genome editing means operably linked to said promoter sequence. The genome editing means is: (a) a means that includes CRISPR/Cas9 formed from the Cas9 protein and guide RNA (gRNA), and a repair gene; or (b) a means that includes CRISPR/Cas9 formed from the Cas9 protein and gRNA. The gRNA includes: a nucleotide region that is complementary to part of a region related to the expression of a disorder-related protein on a patient's genome; and a region that interacts with the Cas9 protein.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• A61K 35/761 - Adenovirus
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 38/43 - EnzymesProenzymesDerivatives thereof
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 7/04 - AntihaemorrhagicsProcoagulantsHaemostatic agentsAntifibrinolytic agents

Abstract

Provided is a treatment method and the like, for example, against novel IL-8 related diseases, said method using an IL-8 signal inhibitor. Alternatively, provided is a treatment method and thelike, for example, against known or novel IL-8 related diseases, said method using a novel anti-IL-8 antibody.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 15/00 - Drugs for genital or sexual disordersContraceptives
• A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• A61P 17/06 - Antipsoriatics
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons

Abstract

For example, therapeutic methods and the like for novel IL-8-related diseases using an IL-8 signal inhibitor are provided. Alternatively, for example, therapeutic methods and the like for known or novel IL-8-related diseases using a novel anti-IL-8 antibody are provided.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 15/00 - Drugs for genital or sexual disordersContraceptives
• A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• A61P 17/06 - Antipsoriatics
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons

Abstract

The purpose of the present invention is to adsorb calciprotein particles. An adsorbent for calciprotein particles according to the present invention is characterized in that at least one selected from among an amino group, a carboxyl group, a phosphate group, a phosphono group, a phosphino group, and a thiol group is covalently bonded to the surface of a water-insoluble carrier via a hydrocarbon group.

IPC Classes  ?

• B01J 20/22 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising organic material
• A61M 1/36 - Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation
• C07K 1/14 - ExtractionSeparationPurification

Abstract

The objective of the present invention is to provide a manipulator with which it is possible for an instrument such as a scope or forceps to be manipulated to a desired position and orientation, and with which interference between medical implements in a trocar or in the abdominal cavity can be avoided, thereby alleviating the load on a surgeon, for example. Another objective of the present invention is to provide a medical implement provided with said manipulator, and a method of evaluating the workability of a manipulator. A manipulator 2 is mounted on a scope 1, and is inserted from the distal end side thereof into an abdominal cavity 9, through an opening 8A which communicates with the interior of the abdominal cavity 9. The manipulator 2 is provided with: a penetrating tube 201 which penetrates through the inside of the opening 8A; a first bent portion 21 which is capable of being bent relative to the penetrating tube 201 inside the abdominal cavity 9; an extending and retracting portion 23 which is capable of being extended and retracted on the distal end side of the first bent portion 21; a first bending manipulation wire 31 for manipulating the first bent portion 21; and an extending and retracting manipulation wire 33 for manipulating the extending and retracting portion 23.

IPC Classes  ?

• A61B 1/313 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for introducing through surgical openings, e.g. laparoscopes
• A61B 1/01 - Guiding arrangements therefor
• A61B 17/94 - Endoscopic surgical instruments
• B25J 18/04 - Arms extensible rotatable

Abstract

The present application relates to a method for reestablishing stem cells capable of forming chimeras, and cells obtained by the method. The method of the present invention is a technique for monocloning stem cells, for example, capable of forming chimeras from a heterogeneous cell population to obtain high-quality stem cells.

IPC Classes  ?

• C12N 5/073 - Embryonic cells or tissuesFoetal cells or tissues
• C12N 5/0735 - Embryonic stem cellsEmbryonic germ cells
• C12N 5/074 - Adult stem cells
• C12N 5/02 - Propagation of single cells or cells in suspensionMaintenance thereofCulture media therefor
• A01K 67/027 - New or modified breeds of vertebrates
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
• C12N 15/09 - Recombinant DNA-technology
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor

Abstract

The present invention relates to a method for reestablishing stem cells having a chimera-forming capacity, by using a multi-stage process. In this method a reestablishment step is performed at least twice, said reestablishment step including a step in which a first type of pluripotent stem cell or a multipotent stem cell is co-cultured with a host embryo having a second type of cell having different culturing conditions to the first stem cells. During this process, in the step in which the first type of stem cell is co-cultured with the host embryo having the second type of cell, a mixed medium of a culture medium suitable for the first type of stem cell and a culture medium suitable for the second type of cells is used as the culture medium and stem cells having a chimera-forming capacity are reestablished. The reestablished stem cells having a chimera-forming capacity can be cultured using any of the culture mediums among: the culture medium suitable for the second type of cells; the culture medium suitable for the first type of stem cells; or a mixed culture of the culture medium suitable for the first type of stem cells and the culture medium suitable for the second type of cells.

IPC Classes  ?

• C12N 5/16 - Animal cells
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 5/26 - Cells resulting from interspecies fusion
• C12N 5/28 - Cells resulting from interspecies fusion one of the fusion partners being a human cell
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms

Abstract

Provided is a novel gene therapy means for neurological diseases including epilepsy. The present invention provides: a recombinant adeno-associated virus vector for use in the treatment of neurological diseases including epilepsy, which contains a polynucleotide encoding a protein capable of improving the excitation-inhibiting function of an inhibitory synapse in vivo, preferably neuroligin-2 protein; a pharmaceutical composition containing the recombinant vector; and others. The present invention also provides a method for treating a disease such as epilepsy using the recombinant vector.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 25/06 - Antimigraine agents
• A61P 25/08 - AntiepilepticsAnticonvulsants
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 25/20 - HypnoticsSedatives
• A61P 25/22 - Anxiolytics
• A61P 25/24 - Antidepressants
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 25/30 - Drugs for disorders of the nervous system for treating abuse or dependence
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
• C12N 15/09 - Recombinant DNA-technology

Abstract

The purpose of the present invention is to provide: a viscoelastic composition that has excellent manipulability and is suitable for uses in which, when an opaque dark liquid accumulates inside a tube and obstructs the field of view of an endoscope, the liquid is pushed away, securing the field of view of the endoscope; and a method for securing the field of view of an endoscope which involves using the viscoelastic composition. The viscoelastic composition for securing the field of view of an endoscope contains water and a substance exhibiting viscoelastic properties, preferably has a hardness of 550 N/m2 or less, a viscosity (25°C) of 200–2,000 mPa·s, a loss tangent of 0.6 or less, and more preferably, an electrical conductivity of 250 µS/cm or less. The method for securing the field of view of an endoscope involves feeding the viscoelastic composition from the proximal part of the endoscope, through a channel, into the distal part of the endoscope.

IPC Classes  ?

• A61L 31/00 - Materials for other surgical articles

Abstract

The purpose of the present invention is to provide: a viscoelastic composition that has excellent manipulability and is suitable for uses in which, when an opaque dark liquid accumulates inside a tube and obstructs the field of view of an endoscope, the liquid is pushed away, securing the field of view of the endoscope; and a method for securing the field of view of an endoscope which involves using the viscoelastic composition. The viscoelastic composition for securing the field of view of an endoscope contains water and a substance exhibiting viscoelastic properties, preferably has a hardness of 550 N/m2 or less, a viscosity (25°C) of 2002,000 mPa·s, a loss tangent of 0.6 or less, and more preferably, an electrical conductivity of 250 µS/cm or less. The method for securing the field of view of an endoscope involves feeding the viscoelastic composition from the proximal part of the endoscope, through a channel, into the distal part of the endoscope.

IPC Classes  ?

• A61L 31/00 - Materials for other surgical articles
• A61B 1/12 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor with cooling or rinsing arrangements

Abstract

The purpose of the present invention is to provide a viscoelastic composition having excellent operability, which is suitable for use in securing the field of view of an endoscope when opaque dark-colored liquid accumulates inside a canal and obstructs the field of view of the endoscope, the viscoelastic cornposition securing the field of view by pushing the liquid aside, and to provide a method for securing the field of view of an endoscope using the viscoelastic composition. The viscoelastic composition for securing the field of view of an endoscope comprises a substance having viscoelastic properties and water, preferably has a hardness of 550 N/m2 or less, a viscosity (25 C) of 200 to 2,000 mPa.s, and a loss tangent of 0.6 or less, and more preferably has an electrical conductivity of 2501.1S/cm or less. The method for securing the field of view of an endoscope comprises feeding the viscoelastic composition from a proximal part of the endoscope, through a channel, into a distal part of the endoscope.

IPC Classes  ?

• A61L 31/00 - Materials for other surgical articles
• A61B 1/12 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor with cooling or rinsing arrangements

Abstract

Provided is a technique for effectively outputting information in such a way that a diagnosis relating to a medical condition of an examinee (patient), or a diagnosis relating to the effect of treatment on the medical condition, can be made objectively. According to this technique, information relating to a subject, and treatment information with respect to the subject, are acquired from a database, and a biological signal is acquired from a measuring unit which measures the biological signal at a prescribed site in the subject. The information relating to the subject, the treatment information and the biological signal are then integrated to generate integrated information. Furthermore, a display process is executed to display simultaneously on a screen of a display device a plurality of types of information contained in the integrated information, as an inspection result display (see figure 13).

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
• G06Q 50/22 - Social work or social welfare, e.g. community support activities or counselling services

Abstract

The invention pertains to a method for preparing hematopoietic cells of primates, characterized by including: a first step for culturing a cell group of pluripotent stem cells of a primate under conditions suited to inducing differentiation into hematopoietic cells, and obtaining a cell group including CD-34 negative cells; a second step for transplanting at least some of the cell group obtained in the first step into the fetus of an animal different from the primate; and a third step for obtaining hematopoietic cells of the primate from the body of the animal obtained by raising the offspring obtained by the birth of the fetus.

IPC Classes  ?

• C12N 5/22 - Human cells
• A01K 67/027 - New or modified breeds of vertebrates
• C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
• C12N 15/09 - Recombinant DNA-technology

Abstract

The present invention relates to an anastomosis connector that is easy to insert into biological tubular tissue at the time of anastomosing first biological tubular tissue and second biological tubular tissue. This anastomosis connector (3) comprises: a wavy circumferential part (20); top-side narrow members (10A-1 to 10A-8); and bottom-side narrow members (10B-1 to 10B-8). The top-side narrow member (10A-1 to 10A-8) is connected to one of the top parts of the wavy circumferential part (20). The bottom-side narrow member (10B-1 to 10B-8) is connected to one of the bottom parts of the wavy circumferential part (20).

IPC Classes  ?

• A61B 17/11 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for performing anastomosisButtons for anastomosis

Abstract

Provided is a technique for computing a brain function index for diagnosing a mental disorder at the individual level, which can be applied to even a child around school age. A brain function index computing device includes a brain activity value calculation processing unit configured to calculate from brain activity signals of a subject a first brain activity value of a region including the meddle frontal gyrus (MFG) and a second brain activity value of a region including the inferior frontal gyrus (IFG); and a brain function index calculation processing unit configured to calculate a brain function index associated with a mental disorder using the first brain activity value and the second brain activity value.

IPC Classes  ?

• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/16 - Devices for psychotechnicsTesting reaction times
• A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
• G06G 7/58 - Analogue computers for specific processes, systems, or devices, e.g. simulators for chemical processes

Abstract

The present application pertains to a method for reestablishing stem cells having a chimera-forming capacity, and to cells obtained by said method. This method is a technique for improving stem cell quality by monoclonally replicating stem cells having a chimera-forming capacity that are selected from a heterogeneous cell population.

IPC Classes  ?

• C12N 5/0735 - Embryonic stem cellsEmbryonic germ cells
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
• A01K 67/027 - New or modified breeds of vertebrates
• C12N 15/09 - Recombinant DNA-technology
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

　The problems addressed by the inventors were to resolve the drawbacks of the prior art and develop a method for efficiently conducting gene modification in pigs, and to make it possible to breed gene-knockout pigs that die before reaching breeding age. In the present invention, a gene-knockout pig individual was produced by preparing gene-knockout pig cells by cutting a target gene using mRNA that encoded zinc finger nuclease specific to the target gene, removing the cell nuclei, transplanting the cells to an enucleated unfertilized egg, and transferring the egg to the uterus of a surrogate mother. Some of the gene-knockout pigs produced in this way die before they can reach breeding age, similarly to the XSCID pig of the embodiments, but it was also shown that gene-knockout pigs capable of breeding can be produced by blastocyst complementation using a normal embryo.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• A01K 67/027 - New or modified breeds of vertebrates
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

Abstract

[Problem] To provide a satiety maintaining agent or method for maintaining a feeling of satisfaction which is capable of maintaining satiety so as to reduce dietary intake by an individual, thereby preventing and improving a condition, such as obesity, that is caused by overeating. [Solution] A satiety maintaining agent that comprises D-psicose as an active ingredient and a method for maintaining a feeling of satisfaction by consuming D-psicose. [Effect] Satiety can be maintained even though a rise in blood glucose level after a meal is suppressed. Thus, a useful means for maintaining satiety can be provided for people who worry about their blood glucose level or who are health-oriented.

IPC Classes  ?

• A61K 31/7004 - Monosaccharides having only carbon, hydrogen and oxygen atoms
• A61P 3/04 - AnorexiantsAntiobesity agents

Abstract

　An information management system (10) is provided with a portable communication terminal (100) capable of acquiring position information, a community medicine databank system (120), and a medical institution (130) provided with a transmitter (131). The portable communication terminal (100) transmits a space-time tag comprising time information and position information, and a terminal ID to the community medicine databank system (120). A space-time ID information processing unit (121) of the community medicine databank system (120) generates, in a per-use folder, a space-time ID from a plurality of space-time tags, and stores the generated space-time ID in a space-time ID information DB (122). A terminal device (133) of the medical institution (130) transmits the position information and time information about the portable communication terminal (100) to the community medicine databank system (120). A collation processing unit (124) collates information from the portable communication terminal (100) and information from a used terminal (141) and, if a request for information transmission is valid, transmits the information to the used terminal (141).

IPC Classes  ?

• G06Q 50/10 - Services
• G06Q 50/22 - Social work or social welfare, e.g. community support activities or counselling services

Abstract

The present invention provides an artificial kidney precursor containing a non-human mammalian metanephros separated out from a living body, wherein the metanephros has been subjected to freezing and thawing treatments outside a living body, and contains mammalian mesenchymal stem cells transferred outside a living body, and a method of production thereof.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• A61K 35/22 - UrineUrinary tract, e.g. kidney or bladderIntraglomerular mesangial cellsRenal mesenchymal cellsAdrenal gland
• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells

Abstract

A cardiovascular risk evaluation apparatus includes a hypoxic acquisition unit for acquiring a measurement result that includes a blood oxygen saturation level measured in a hypoxic period in which the blood oxygen saturation level of a subject is lower than a threshold value, and a blood pressure measured when the blood oxygen saturation level was measured; a non-hypoxic acquisition unit for acquiring a measurement result that includes a blood oxygen saturation level measured in a non-hypoxic period of the blood oxygen saturation level of the subject, and a blood pressure measured when the blood oxygen saturation level was measured; and an indicator acquisition unit for acquiring a cardiovascular risk evaluation indicator for the subject based on the relationship between blood oxygen saturation level and blood pressure, which is based on the measurement results acquired by the hypoxic acquisition unit and the non-hypoxic acquisition unit.

IPC Classes  ?

• A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
• A61B 5/0205 - Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/022 - Measuring pressure in heart or blood vessels by applying pressure to close blood vessels, e.g. against the skinOphthaldynamometers

Abstract

A blood pressure measurement apparatus for measuring blood pressure in a predetermined period includes a blood pressure measuring unit for measuring the blood pressure of a subject, an information acquiring unit for acquiring information that is related to variation in blood pressure and changes in a time-series in the predetermined period, a determining unit for determining whether or not the information acquired by the information acquiring unit satisfies a predetermined condition, and a trigger output unit for, in a case where the determining unit determines that the predetermined condition is satisfied, causing the blood pressure measuring unit to start and execute blood pressure measurement. The predetermined condition is expressed as a function of time that varies and is measured in the predetermined period.

IPC Classes  ?

• A61B 5/02 - Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
• A61B 5/0205 - Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/0225 - Measuring pressure in heart or blood vessels by applying pressure to close blood vessels, e.g. against the skinOphthaldynamometers the pressure being controlled by electric signals, e.g. derived from Korotkoff sounds
• A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
• A61B 5/08 - Measuring devices for evaluating the respiratory organs
• A61B 5/024 - Measuring pulse rate or heart rate
• A61B 5/022 - Measuring pressure in heart or blood vessels by applying pressure to close blood vessels, e.g. against the skinOphthaldynamometers

Abstract

The present invention provides a mammalian stem cell suspension containing mammalian stem cells and at least one polysaccharide such as trehalose, and the like; a mammalian stem cell aggregation inhibitor containing polysaccharide such as trehalose, and the like; a method of suppressing aggregation of mammalian stem cells, containing suspending the mammalian stem cells in an aqueous physiological solution containing polysaccharide; an inhibitor of a decrease in the survival rate of mammalian stem cells containing polysaccharide such as trehalose and the like; a method of suppressing a decrease in the survival rate of mammalian stem cells, containing suspending the mammalian stem cells in an aqueous physiological solution containing polysaccharides, and the like.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C07H 3/04 - Disaccharides
• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• A01N 1/02 - Preservation of living parts
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• C08B 31/04 - Esters of organic acids
• C08B 37/02 - DextranDerivatives thereof

Abstract

The present invention provides a means for transferring a therapeutic gene of interest into a nervous system cell by a highly-efficient and simpler means. More specifically, the present invention provides a recombinant vector that uses an adeno-associated virus (AAV), a method for manufacturing the recombinant vector, and a method for using the recombinant vector. More specifically, recombinant adeno-associated virus virions, which are capable of passing through the brain-brain barrier, for transferring a therapeutic genes of interest into a nervous system cell in a highly-efficient manner, a drug composition containing the recombinant adeno-associated virus virions, a method for manufacturing the recombinant adeno-associated virus virions, and a kit or the like are provided.

IPC Classes  ?

• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61K 38/44 - Oxidoreductases (1)
• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• C12N 15/861 - Adenoviral vectors
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/86 - Viral vectors
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 38/18 - Growth factorsGrowth regulators